Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCYNEXIS Signs Deal with R-Pharm

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
First oral glucan synthase inhibitor ready to enter phase 2 trials.

SCYNEXIS, Inc. and R-Pharm have announced that they have entered into an agreement granting R-Pharm exclusive rights to develop and commercialize SCY-078 in Russia and several other markets.

SCYNEXIS retains the rights to market the compound in The Americas, Europe and Asia. SCY-078 is an oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases such as candidemia and aspergillosis.

“Glucan synthase inhibitors have been very effective in treating invasive fungal infections in a hospital setting, but are currently only available as an intravenous dosing option,” said Alexey Repik, president and chairman, R-Pharm.

Repik continued, “As the first oral glucan synthase inhibitor, SCY-078 could prove very useful in markets where intravenous dosing options have resulted in under treatment or treatment limitations.”

“This partnership with R-Pharm is an important milestone in the advancement of SCY-078 toward Phase 2 clinical development and beyond,” said Yves Ribeill, Ph.D., president and chief executive officer, SCYNEXIS. “We welcome R-Pharm’s contributions to the development and commercialization of SCY-078, which provides us access to some very important and potentially large markets, including Russia.”

Under the terms of this agreement, R-Pharm will develop and register SCY-078 in its territories including Russia, The Commonwealth of Independent States and Turkey.

SCYNEXIS receives an upfront payment and is entitled to receive payments on development and commercialization milestones and royalties. Further details of the agreement are not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!